Adaptimmune Therapeutics PLC
ADAP0.283USD
-0.002-1.01%
收盤 06/06, 16:00（美東）報價延遲15分鐘
437.83M總市值
虧損本益比TTM
關於 Adaptimmune Therapeutics PLC 公司
Adaptimmune Therapeutics PLC 是一家臨牀階段的生物製藥公司。該公司專注於爲癌症患者提供細胞療法。其工程化 T 細胞受體 (TCR) 平臺能夠對 T 細胞進行工程化，以靶向和摧毀多種實體腫瘤類型的癌症。其細胞療法候選藥物包括 TCR T 細胞和 TruC T 細胞。其產品候選藥物包括 afamitresgene autoleucel (afami-cel) 和 Lete-cel。afamicel 是一種細胞療法，可爲滑膜肉瘤患者提供治療選擇。該公司正在過渡 lete-cel，該療法針對滑膜肉瘤和粘液樣圓細胞脂肪肉瘤 (MRCLS) 患者的 NY-ESO 抗原。其臨牀管線包括 ADP-A2M4CD8 的 SURPASS-III II 期試驗和 ADP-A2M4CD8 的 SURPASS I 期試驗。該公司最先進的臨牀前項目是針對 PRAME 靶點 (ADP-600) 和 CD70 (ADP-520) 的 T 細胞療法。ADAP-600 是一種工程化的 TCR T 細胞。
公司簡介
公司代碼ADAP
公司名稱Adaptimmune Therapeutics PLC
上市日期May 06, 2015
成立日期2014
CEOMr. Adrian Rawcliffe
員工數量506
證券類型Depository Receipt
年結日May 06
公司地址60 Jubilee Avenue
城市ABINGDON
上市交易所NASDAQ Capital Market Consolidated
國家United Kingdom
郵編OX14 4RX
電話441235430000
網址https://www.adaptimmune.com/
公司代碼ADAP
上市日期May 06, 2015
成立日期2014
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Garry E. Menzel, Ph.D.
Dr. Garry E. Menzel, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
611.22K
+191.15%
Mr. John Lunger
Mr. John Lunger
Chief Patient Supply Officer
Chief Patient Supply Officer
170.89K
+53.91%
Dr. Elliot Norry, M.D.
Dr. Elliot Norry, M.D.
Chief Medical Officer
Chief Medical Officer
133.26K
+99.32%
Ms. Cintia Piccina
Ms. Cintia Piccina
Chief Commercial Officer
Chief Commercial Officer
111.07K
+559.70%
Mr. Lawrence M. (Larry) Alleva, CPA
Mr. Lawrence M. (Larry) Alleva, CPA
Non-Executive Independent Director
Non-Executive Independent Director
23.89K
--
Mr. Adrian Rawcliffe
Mr. Adrian Rawcliffe
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. William C. (Bill) Bertrand, Jr., Esq.
Mr. William C. (Bill) Bertrand, Jr., Esq.
Chief Operating Officer
Chief Operating Officer
--
--
Mr. John P. Furey
Mr. John P. Furey
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Joanna Brewer, Ph.D.
Dr. Joanna Brewer, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Garry E. Menzel, Ph.D.
Dr. Garry E. Menzel, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
611.22K
+191.15%
Mr. John Lunger
Mr. John Lunger
Chief Patient Supply Officer
Chief Patient Supply Officer
170.89K
+53.91%
Dr. Elliot Norry, M.D.
Dr. Elliot Norry, M.D.
Chief Medical Officer
Chief Medical Officer
133.26K
+99.32%
Ms. Cintia Piccina
Ms. Cintia Piccina
Chief Commercial Officer
Chief Commercial Officer
111.07K
+559.70%
Mr. Lawrence M. (Larry) Alleva, CPA
Mr. Lawrence M. (Larry) Alleva, CPA
Non-Executive Independent Director
Non-Executive Independent Director
23.89K
--
Mr. Adrian Rawcliffe
Mr. Adrian Rawcliffe
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 5月21日 週三
更新時間: 5月21日 週三
持股股東
股東類型
持股股東
股東統計
佔比
EcoR1 Capital, LLC
10.34%
Long Focus Capital Management LLC
8.96%
Two Seas Capital LP
7.75%
New Enterprise Associates (NEA)
6.44%
MPM Capital Inc.
2.01%
Other
64.50%
持股股東
股東統計
佔比
EcoR1 Capital, LLC
10.34%
Long Focus Capital Management LLC
8.96%
Two Seas Capital LP
7.75%
New Enterprise Associates (NEA)
6.44%
MPM Capital Inc.
2.01%
Other
64.50%
股東類型
股東統計
佔比
Hedge Fund
18.51%
Investment Advisor/Hedge Fund
16.38%
Venture Capital
6.44%
Research Firm
1.46%
Investment Advisor
1.40%
Individual Investor
0.63%
Pension Fund
0.07%
Other
55.11%
機構持股
更新時間: 2月22日 週六
更新時間: 2月22日 週六
報告期間
機構數
持股數
持股佔比
持股變動
2025Q1
190
114.17M
43.26%
-32.76M
2024Q4
195
128.66M
50.28%
-22.55M
2024Q3
199
155.41M
60.76%
-9.79M
2024Q2
202
157.35M
61.56%
-15.41M
2024Q1
213
165.17M
64.85%
-7.14M
2023Q4
210
146.11M
64.44%
-17.89M
2023Q3
229
151.45M
66.86%
-8.97M
2023Q2
226
147.93M
65.80%
+13.35M
2023Q1
200
118.51M
71.56%
-15.30M
2022Q4
207
116.34M
70.73%
-22.36M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
EcoR1 Capital, LLC
27.40M
10.65%
--
--
Dec 31, 2024
Long Focus Capital Management LLC
20.49M
7.97%
+7.19M
+54.09%
Dec 31, 2024
Two Seas Capital LP
14.84M
5.77%
+14.84M
--
Dec 31, 2024
New Enterprise Associates (NEA)
17.08M
6.64%
--
--
Dec 31, 2024
MPM Capital Inc.
5.56M
2.16%
--
--
Dec 31, 2024
MPM BioImpact LLC
5.10M
1.98%
--
--
Dec 31, 2024
Morgan Stanley & Co. LLC
1.01M
0.39%
-265.02K
-20.74%
Dec 31, 2024
Rock Springs Capital Management LP
2.48M
0.97%
+58.00K
+2.39%
Dec 31, 2024
Acadian Asset Management LLC
510.22K
0.2%
+510.22K
--
Dec 31, 2024
Renaissance Technologies LLC
2.53M
0.98%
+869.95K
+52.51%
Dec 31, 2024
查看更多
持股ETF
更新時間: 6月6日 週五
更新時間: 6月6日 週五
機構名稱
佔比
Invesco NASDAQ Future Gen 200 ETF
0.33%
SPDR S&P International Small Cap ETF
0.01%
Fidelity Enhanced Small Cap ETF
0%
ActivePassive International Equity ETF
0%
SPDR Portfolio Developed World ex-US ETF
0%
Simplify Propel Opportunities ETF
0%
ProShares Ultra Nasdaq Biotechnology
0%
iShares Biotechnology ETF
0%
Invesco Nasdaq Biotechnology ETF
0%
Invesco NASDAQ Future Gen 200 ETF
佔比0.33%
SPDR S&P International Small Cap ETF
佔比0.01%
Fidelity Enhanced Small Cap ETF
佔比0%
ActivePassive International Equity ETF
佔比0%
SPDR Portfolio Developed World ex-US ETF
佔比0%
Simplify Propel Opportunities ETF
佔比0%
ProShares Ultra Nasdaq Biotechnology
佔比0%
iShares Biotechnology ETF
佔比0%
Invesco Nasdaq Biotechnology ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
